Do Hun Kim (WHITE LAB)

Identification and Investigation of Immunological Drug Response Mechanisms in Glioblastoma

Glioblastoma is a devastating form of adult brain cancer with 5% five-year survival rate, whichTemozolomide is the only available treatment option for patients. However, immunotherapy could serve as an alternative to bypass this problem. We robustly analyze the pMHC both in vitro and in vivo to identify targetable antigens using mass spectrometry. Underlying mechanism behind such overexpression will be investigated and validated for future development of combination immunotherapy.

Catherine Henry (KOEHLER LAB)

Developing High-throughput, Quantitative Platforms to Identify the Targets of Small Molecules

Target identification is a major bottleneck in academic and industry labs. Current approaches are unable to reliably detect interactions between small molecules and protein targets in complex biological systems. These methods are especially limited in their ability to monitor weak interactions or low-abundance targets. Here, I will discuss the generalizable, high-throughput platforms we are developing to rapidly identify the mechanism(s) of action of small molecules emerging from high-throughput screening campaigns.